OpenOnward
Open systems to expedite the scientific process
Find and donate to over 250 non-profit foundations supporting biomedical research
11/19/2017
"U.S. Food and Drug Administration is concerned that some patients seeking cures and remedies are vulnerable to stem cell treatments that are illegal and potentially harmful. And the FDA is increasing its oversight and enforcement to protect people from dishonest and unscrupulous stem cell clinics, while continuing to encourage innovation so that the medical industry can properly harness the potential of stem cell products."
FDA Warns About Stem Cell Therapies Stem cells have been called everything from cure-alls to miracle treatments. But don't believe the hype. The U.S. Food and Drug Administration is concerned that some patients may be vulnerable to stem cell treatments that are illegal and potentially harmful. Here's what to know before you consider s...
Regenerative medicine gets a boost from new FDA guidance for drug development
FDA announces comprehensive regenerative medicine policy framework FDA announces comprehensive regenerative medicine policy framework to spur innovation, efficient access to potentially transformative products, while ensuring safety and efficacy.
11/15/2017
Historic event in medicine today: First patient dosed with genome-editing therapy.
Sangamo Announces Treatment of First Patient in Landmark Phase 1/2 Clinical Trial Evaluating In Vivo Genome Editing for MPS II :: Sangamo Therapeutics, Inc. (SGMO) Sangamo Announces Treatment of First Patient in Landmark Phase 1/2 Clinical Trial Evaluating In Vivo Genome Editing for MPS II Download as PDF November 15, 2017 RICHMOND, Calif., Nov. 15, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced treatment of the first patient in...
American Cancer Society - 2017 Cancer Facts and Figures: About 1.7 million new cancer cases and over 600,000 deaths expected this year.
11/02/2017
CAR-T therapies are doing well (Novartis, Gilead/Kite, and Juno).
Juno touts latest cancer drug results after rivals Kite and Novartis win FDA approval - Puget Sound Business Journal Juno Therapeutics announced new cancer trial results that could help the drugmaker leapfrog key competitors in the rapidly emerging cancer immunotherapy industry.
11/01/2017
Novartis asks FDA to expand Kymriah's use against blood cancer Swiss drugmaker Novartis is seeking U.S. regulators' blessing for its Kymriah cell therapy to be used against a second form of blood cancer after winning initial approval for the treatment earlier this year.
10/05/2017
Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine - Preliminary Report. - PubMed - NCBI N Engl J Med. 2017 Oct 4. doi: 10.1056/NEJMoa1708120. [Epub ahead of print]
Inovio’s Positive Zika Vaccine Clinical Study Data Published in New England Journal of Medicine PLYMOUTH MEETING, Pa., Oct. 05, 2017-- Inovio Pharmaceuticals, Inc. reported today on positive safety and immune response results from a first-in-man, multi-center phase 1 trial of a vaccine against the ...
10/04/2017
Cancer immunotherapy - Wikipedia Cancer immunotherapy (Immuno-oncology or Immunooncology) is the use of the immune system to treat cancer. Immunotherapies can be categorized as active, passive or hybrid (active and passive). These approaches exploit the fact that cancer cells often have molecules on their surface that can be detect...
10/04/2017
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma — NEJM Original Article from The New England Journal of Medicine — Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
10/02/2017
Circadian rhythm wins Nobel Prize in Medicine
Nobel Prize in Medicine Awarded for Discoveries About Circadian Rhythm Jeffrey C. Hall, Michael Rosbash and Michael W. Young were recognized for research into the cellular mechanisms controlling the body’s 24-hour cycle.
Click here to claim your Sponsored Listing.
Category
Website
Address
21231